[{"orgOrder":0,"company":"Chord Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2021","type":"Acquisition","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Immunology","graph2":"Preclinical","graph3":"Chord Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chord Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Chord Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Mysthera Therapeutics","sponsor":"Forty51 Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Mysthera Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mysthera Therapeutics \/ Forty51 Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Mysthera Therapeutics \/ Forty51 Ventures"},{"orgOrder":0,"company":"Antion Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"miCAR19","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Antion Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antion Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Antion Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MetrioPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MP1032","moa":"Macrophage","graph1":"Immunology","graph2":"Preclinical","graph3":"MetrioPharm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MetrioPharm \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"MetrioPharm \/ Inapplicable"},{"orgOrder":0,"company":"ImmunOs Therapeutics","sponsor":"Eurostars","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2021","type":"Funding","leadProduct":"OCi mAb","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"ImmunOs Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunOs Therapeutics \/ Eurostars","highestDevelopmentStatusID":"4","companyTruncated":"ImmunOs Therapeutics \/ Eurostars"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Exogenus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2025","type":"Collaboration","leadProduct":"Exo-101","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Group \/ Exogenus Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Group \/ Exogenus Therapeutics"},{"orgOrder":0,"company":"GlycoEra","sponsor":"Novo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2025","type":"Series B Financing","leadProduct":"GE8820","moa":"IgG4","graph1":"Immunology","graph2":"Preclinical","graph3":"GlycoEra","amount2":0.13,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.13,"dosageForm":"Undisclosed","sponsorNew":"GlycoEra \/ Novo Holdings","highestDevelopmentStatusID":"4","companyTruncated":"GlycoEra \/ Novo Holdings"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The financing aims to advance the clinical development of company's lead product GE8820, which is being evaluated for the autoimmune diseases such as pemphigus, primary membranous nephropathy etc.

                          Product Name : GE8820

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          May 27, 2025

                          Lead Product(s) : GE8820

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Sponsor : Novo Holdings

                          Deal Size : $130.0 million

                          Deal Type : Series B Financing

                          blank

                          02

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The collaboration aims to develop Exo-101, Exogenus’ exosome-based lead candidate. It is derived from immunologically privileged cells from umbilical cord blood, being evaluating for fibrosis.

                          Product Name : Exo-101

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          March 11, 2025

                          Lead Product(s) : Exo-101

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Sponsor : Exogenus Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : miCAR19, is an anti-CD19 CAR T-cell &gene therapy candidate, which is currently being evaluated for the treatment of B-cell driven autoimmune diseases.

                          Product Name : miCAR19

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          May 22, 2024

                          Lead Product(s) : miCAR19

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The capital will be used to advance its portfolio of pre-clinical stage, pan-PIM kinase inhibitors to uniquely modulate multi-lineage immune cell functions.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          August 21, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Sponsor : Forty51 Ventures

                          Deal Size : $3.5 million

                          Deal Type : Financing

                          blank

                          05

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The company entered into an agreement to secure the global rights by acquiring Chord Therapeutics, a company focused on rare neuroinflammatory diseases. Acquisition provides opportunity to develop cladribine in Myasthenia Gravis and Neuromyelitis Optica ...

                          Product Name : Mavenclad

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Undisclosed

                          December 20, 2021

                          Lead Product(s) : Cladribine

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Sponsor : Merck & Co

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          06

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The results confirm the very good safety profile of MetrioPharm's lead compound MP1032. They allow for long-term clinical studies in chronic indications to be conducted in the future.

                          Product Name : MP1032

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 04, 2021

                          Lead Product(s) : MP1032

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The funds have been granted for the development of a pioneering HLA-open conformer-specific antibody to treat chronic inflammatory rheumatic diseases.

                          Product Name : Undisclosed

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          April 13, 2021

                          Lead Product(s) : OCi mAb

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Sponsor : Eurostars

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank